Skip to Main Content

Top of the morning to you. Another deliciously shiny day is unfolding over the Pharmalot campus, where the skies are blue and a cool breeze is circulating. Although there is much work to be done, please join us as we pause ever so briefly to relish the moment with a tasty cup of stimulation — our choice today is peppermint mocha. After all, life is short, so why not stop to appreciate, yes? Once you’ve finished, you can dig in to the menu of interesting items below. And of course, have a wonderful day. …

Drugmakers are trying to blunt Medicare’s newfound power to negotiate medicine prices while coping with internal industry disputes and ebbing influence in Washington, D.C., The Wall Street Journal reports. Yet the lobbying comes without some key lawmakers in the industry’s corner, and at a moment when one of its biggest trade groups, the Biotechnology Innovation Organization, must find a new leader after its chief executive clashed with board members and resigned. BIO and the Pharmaceutical Research and Manufacturers of America, the other major trade group, said the law threatened investment in drug development while not doing enough to lower patient drug costs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment